Arvinas (ARVN) Stock Overview
A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ARVN Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Arvinas, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.92 |
| 52 Week High | US$14.51 |
| 52 Week Low | US$5.90 |
| Beta | 1.94 |
| 1 Month Change | -11.22% |
| 3 Month Change | -10.27% |
| 1 Year Change | 37.36% |
| 3 Year Change | -60.82% |
| 5 Year Change | -83.48% |
| Change since IPO | -31.96% |
Recent News & Updates
Recent updates
Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth
Jan 27
Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating
Nov 24Improved Revenues Required Before Arvinas, Inc. (NASDAQ:ARVN) Stock's 26% Jump Looks Justified
Sep 09We're Not Very Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Rate
Jun 01Arvinas, Inc.'s (NASDAQ:ARVN) Shares Bounce 37% But Its Business Still Trails The Industry
May 01
Phase III And PROTAC Data Will Advance Pipeline Despite Hurdles
Successful trials and partnerships in oncology could support Arvinas' transition to commercial operations, driving growth and revenue potential.Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects
Mar 14Arvinas, Inc. (NASDAQ:ARVN) Not Doing Enough For Some Investors As Its Shares Slump 56%
Mar 12Arvinas' Vepdegestrant: Why The Data May Not Hold Up
Dec 25Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans
Dec 24Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)
Nov 28Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause
Oct 16Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aug 02Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive
Jul 12Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation
Jun 27Arvinas: Behind The Huge Rally
Mar 03What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You
Feb 25Shareholder Returns
| ARVN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.3% | 0.7% | -0.1% |
| 1Y | 37.4% | 23.1% | 15.9% |
Return vs Industry: ARVN exceeded the US Pharmaceuticals industry which returned 19.3% over the past year.
Return vs Market: ARVN exceeded the US Market which returned 13.3% over the past year.
Price Volatility
| ARVN volatility | |
|---|---|
| ARVN Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ARVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARVN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 246 | Randy Teel | www.arvinas.com |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer.
Arvinas, Inc. Fundamentals Summary
| ARVN fundamental statistics | |
|---|---|
| Market cap | US$658.16m |
| Earnings (TTM) | -US$80.80m |
| Revenue (TTM) | US$262.60m |
Is ARVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARVN income statement (TTM) | |
|---|---|
| Revenue | US$262.60m |
| Cost of Revenue | US$0 |
| Gross Profit | US$262.60m |
| Other Expenses | US$343.40m |
| Earnings | -US$80.80m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.26 |
| Gross Margin | 100.00% |
| Net Profit Margin | -30.77% |
| Debt/Equity Ratio | 0.09% |
How did ARVN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/25 13:17 |
| End of Day Share Price | 2026/03/25 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arvinas, Inc. is covered by 28 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Tazeen Ahmad | BofA Global Research |